Dr. Laura Pizzi is Associate Chief Science Officer, ISPOR. For the past 20 years, she has led interdisciplinary teams of outcomes methodologists, statisticians, and clinicians to develop and conduct cost and outcome analyses on pharmacological therapies as well as a variety of non-pharmacological interventions. A particular interest is developing scientific evidence to inform the U.S. translation and implementation of cost effective interventions to improve the quality of care for older adults. She has testified before the US House of Representatives Committee on Ways and Means on Medicare overspending in beneficiaries with end stage renal disease., co-directed an Agency for Healthcare Research and Quality (AHRQ) evaluation on pharmaceutical quality, and co-edited a text on economic evaluation of health interventions. She is a member of the Editorial Board for the journal PharmacoEconomics, Deputy Editor of American Health and Drug Benefits, and Chair of the ISPOR Faculty Advisor Council. She has published more than 90 peer-reviewed manuscripts and 1110 peer reviewed poster or podium presentations and has over 15 years of teaching and mentoring experience which has been recognized through faculty awards.